These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 3523572)

  • 41. Practical clinical trials for schizophrenia.
    Stroup S
    Epidemiol Psichiatr Soc; 2005; 14(3):132-6. PubMed ID: 16255159
    [No Abstract]   [Full Text] [Related]  

  • 42. Double-blind trials.
    Newcombe RG
    Br J Psychiatry; 1990 Feb; 156():282. PubMed ID: 2180531
    [No Abstract]   [Full Text] [Related]  

  • 43. Challenges Associated With Neuropharmacological Challenge Studies.
    Mathalon DH
    Biol Psychiatry; 2020 Nov; 88(9):670-672. PubMed ID: 33032692
    [No Abstract]   [Full Text] [Related]  

  • 44. No evidence of antipsychotic effect of caerulein in schizophrenic patients free of neuroleptics: a double-blind cross-over study.
    Lotstra F; Verbanck P; Mendlewicz J; Vanderhaeghen JJ
    Biol Psychiatry; 1984 Jun; 19(6):877-82. PubMed ID: 6378259
    [No Abstract]   [Full Text] [Related]  

  • 45. Is cholecystokinin therapeutic in chronic schizophrenia?
    Boza RA; Rotondo DJ
    J Clin Psychiatry; 1985 Nov; 46(11):485-6. PubMed ID: 3902807
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Clinical evaluation of caeruletide (883-S) in chronic schizophrenia].
    Kudo Y
    Seishin Shinkeigaku Zasshi; 1983; 85(11):797-801. PubMed ID: 6146148
    [No Abstract]   [Full Text] [Related]  

  • 47. [Ceruletide as an analgesic in biliary and nephritic colic: comparative study].
    Tura F; Iriarte JL; Bona X; Millá J
    Med Clin (Barc); 1986 Feb; 86(7):277-80. PubMed ID: 3520181
    [No Abstract]   [Full Text] [Related]  

  • 48. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Difficulties of evaluation of the results of drug treatment of schizophrenia].
    Welbel L
    Psychiatr Pol; 1980; 14(1):51-7. PubMed ID: 6102774
    [No Abstract]   [Full Text] [Related]  

  • 50. Limitations of controlled augmentation trials in schizophrenia.
    Stern RG; Schmeidler J; Davidson M
    Biol Psychiatry; 1997 Jul; 42(2):138-43. PubMed ID: 9209731
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical evaluation of ceruletide in schizophrenia: a multi-institutional cooperative double-blind controlled study.
    Itoh H; Shimazono Y; Kawakita Y; Kudo Y; Satoh Y; Takahashi R
    Psychopharmacol Bull; 1986; 22(1):123-8. PubMed ID: 3523572
    [No Abstract]   [Full Text] [Related]  

  • 52. Ceruletide for schizophrenia: a review.
    Mattes JA; Hom W; Rochford JM
    Psychopharmacol Bull; 1986; 22(1):119-22. PubMed ID: 3523571
    [No Abstract]   [Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.